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Abstract
Background: General practitioners (GPs) frequently order blood tests when they see patients presenting with 
unexplained complaints. Due to the low prevalence of serious pathology in general practice, the risk of false- 
positive test results is relatively high. This may result in unnecessary further testing, leading to unfavourable effects 
such as patient anxiety, high costs, somatisation and morbidity. A  policy of watchful waiting is expected to lower 
both the number of patients to be tested and the risk of false-positive test results, without missing serious 
pathology. However, many general practitioners experience barriers when trying to postpone blood testing by 
watchful waiting. The objectives of this study are ( l )  to determine the accuracy of blood tests in patients 
presenting with unexplained complaints in terms of detecting pathology, (2) to determine the accuracy of a 
watchful waiting strategy and (3) to determine the effects of a quality improvement strategy to promote the 
postponement of blood test ordering by GPs for patients with unexplained complaints.
Design: General practices are randomised over three groups. Group l is instructed to order blood tests 
immediately, group 2 to apply a watchful waiting policy and group 3 also to postpone testing, but supported by 
our quality improvement strategy. The trial consists of two sub-studies: a diagnostic study at patient level (group
l versus groups 2 and 3) and a quality improvement study at GP level (group 2 versus group 3). The diagnostic
strategy to be used involves of both customary and innovative tests. The quality improvement strategy consists 
of two small-group meetings and a practice outreach visit. Patient follow-up ends at l2  months after the initial 
consultation. Primary outcome measures are the accuracy and added value of blood tests for detecting pathology, 
the effect of a 4-week postponement of test ordering on the blood test characteristics and the quantity of tests 
ordered. Secondary outcome measures are the course of complaints, quality of life, satisfaction with care, anxiety 
of patients and practitioners, determinants of physicians' behaviour, health care utilisation and costs.
Discussion: The innovative aspect of this trial is that it combines a clinical-epidemiological study and a quality of 
care study.
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Background 
Unexplained complaints
'Unexplained complaints' can be defined as: those com­
plaints for which a general practitioner (GP), after clarify­
ing the reason for encounter, taking history and 
performing physical examination, is unable to establish a 
diagnosis.[1] This definition reflects a broad continuum 
of clinical pictures, ranging from complaints of recent 
onset to more chronic situations in which the physician is 
convinced that somatic disease is absent. Newly presented 
unexplained complaints will in most cases be self-limit­
ing, but they can also develop into chronic complaints, or 
might be the first sign of serious disease.[2] Since GPs are 
usually the first health care professionals patients present 
their complaints to, these complaints belong to the partic­
ular expertise of GPs, who are used to deal with this type 
of complaints autonomously, without referring the 
patients to hospital.
On average, 13% of consultations involve complaints 
considered unexplained by the GP.[3] Although only a 
small minority of these lead to chronicity or serious dis­
ease, additional diagnostic testing is often done after his­
tory taking and physical examination.[4,5]
Blood test ordering
It has frequently been suggested that immediate test 
ordering in unexplained complaints is superfluous.[6-8] 
Since the pretest probability of serious pathology in 
patients with unexplained complaints is usually low, the 
risk of false-positive test results is relatively high. This may 
result in a chain of unnecessary further testing, which in 
turn might lead to patient anxiety, high costs, somatisa­
tion and a risk of serious side effects or even unnecessary 
morbidity. [9,10] Applying a watchful waiting policy is 
recommended because the majority of these complaints 
are expected to be self-limiting. Patients in whom the 
complaints are not self-limiting will have a higher prior 
probability of having serious pathology, and the diagnos­
tic accuracy of tests in this selected group is expected to be 
higher, because of the lower risk of false-positive test 
results.
We have found only one guideline on blood test ordering 
for unexplained complaints in general practice. This 
guideline, issued by the Dutch College of General Practi­
tioners (NHG), recommends an initial watchful waiting 
strategy. If a complaint persists, it recommends ordering a 
limited number of tests (glucose, haemoglobin (Hb), 
erythrocyte sedimentation rate (ESR) and thyroid stimu­
lating hormone (TSH)).[1,11]
However, these test recommendations are based on the­
ory and consensus rather than on evidence. Moreover, in 
practice, more blood tests are ordered, or the watchful
waiting strategy is not followed. Little is known about the 
accuracy or additional value of diagnostic blood tests or 
combinations of such tests, in addition to signs, symp­
toms and environmental and psychosocial factors, for the 
purpose of discriminating between self-limiting unex­
plained complaints and pathology. In addition, the accu­
racy of some newer tests, such as the carbohydrate 
deficient transferrin (CDT) test for the detection of 
pathology in patients with unexplained complaints in 
general practice, is not yet known.[12] Furthermore, sev­
eral questions concerning the non-diagnostic effects of 
test ordering, e.g. on patient and doctor anxiety, remain 
unanswered. Apart from their diagnostic purposes, GPs 
frequently order tests for more strategic reasons, e.g. to 
prevent referral to a specialist or to make the psychosocial 
nature of complaints more acceptable to the patient, 
thereby anticipating normal blood test results. [11]
Improvement of test ordering
Though formal evidence is lacking, one can conclude 
from the high volume of tests ordered by GPs and the low 
probability of pathology that there is room for improve­
ment to GPs' blood test ordering behaviour for patients 
presenting with unexplained complaints.[13,14] It is gen­
erally accepted that strategies to improve professionals' 
behaviour need to be developed systematically, based on 
barriers to and facilitators of the target behaviour. [15] 
Determinants of blood test ordering by GPs for patients 
with unexplained complaints include not only a lack of 
knowledge about the diagnostic value of blood testing but 
also practice routines, GPs' tolerance of uncertainty, expe­
rienced pressure from patients, tactical motives and the 
perceived need to reassure patients.[11] This means that a 
strategy aimed at reducing test ordering by professionals 
should not only focus on improving diagnostic knowl­
edge but also on skills such as dealing with uncertainty 
and patient pressure and applying alternative modes to 
reassure patients. The different types of objectives require 
adequate and tailored methods of instruction, e.g. teach­
ing a skill requires practising rather than lecturing only. 
Since patients also seem to play a role in the decision 
process to order tests, it may be valuable to focus a strategy 
on patients as well, in order to achieve greater effects.
Objectives of the study
The first objective of the ongoing study presented here is 
to determine the accuracy of diagnostic blood tests or 
combinations of such tests and their value, in addition to 
signs, symptoms and contextual factors, for the purpose of 
discriminating between self-limiting diseases and serious 
pathology in patients presenting with unexplained com­
plaints. The second objective is to compare the accuracy of 
a watchful waiting strategy with that of immediate test 
ordering. The third objective is to evaluate the effects of a 
systematically designed quality improvement strategy for
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GPs, aiming at the postponement of blood test ordering 
in patients with unexplained complaints.
Research questions
1. What is the course of complaints that are considered 
unexplained by GPs over a period of one year?
2. What is the diagnostic accuracy of blood tests, relative 
to and in addition to combinations of signs and symp­
toms, for the purpose of discriminating between self-lim­
iting complaints and early stages of pathology in patients 
presenting with unexplained complaints?
3. What is the cost-effectiveness of a 4-week watchful wait­
ing policy compared to immediate test ordering in 
patients presenting with unexplained complaints? 'Costs' 
in this respect include direct medical costs, absence from 
work and immaterial costs such as patients' uncertainty, 
satisfaction and quality of life.
4. What is the cost-effectiveness of a systematically devel­
oped strategy to improve GPs' test ordering behaviour, 
compared to merely instructing them to postpone testing?
Cooperation
The departments of General Practice of the University of 
Maastricht and of the Academic Medical Center-Univer­
sity of Amsterdam are cooperating in this study. Data col­
lection ended on December 31, 2004. At the time of 
writing of this protocol article, we are engaged in data 
cleaning and analysis.
Ethical approval and informed consent procedure
Ethical approval
The medical ethics committees of both the Academic 
Medical Center-University of Amsterdam and the Univer­
sity Hospital Maastricht have approved the study.
Informed consent procedure
GPs hand out written information and an informed con­
sent form to eligible patients. Patients are given the oppor­
tunity to read the information and think about 
participation before signing the consent form. Patients in 
group 1 are fully informed about the trial. Patients in 
groups 2 and 3 are kept naive about the possibility of 
immediate blood test ordering. This is because it is impos­
sible to blind patients for the test group they are in (imme­
diate or postponed blood test ordering). Bias could be 
caused by selective dropout of patients and by a Haw­
thorne effect, as patients can be expected to prefer imme­
diate test ordering over a watchful waiting policy. Patients 
in groups 2 and 3 are told that the study investigates the 
way their GPs manage patients with unexplained com­
plaints.
Design
Operationalisation o f 'unexplained complaints'
Of the complaints that are considered unexplained by GPs 
according to the definition drawn up by the Dutch Col­
lege of General Practitioners (NHG), the following 5 were 
selected: fatigue, abdominal complaints, musculoskeletal 
complaints, itch and weight changes. These were selected 
on the basis of the following criteria: commonly seen 
unexplained complaints in general practice, frequent 
ordering of blood tests and the possibility that clinically 
relevant underlying diseases are detected by blood tests.
Clustered randomised clinical trial
Participating general practices are randomised over 3 
groups (figure 1). GPs in group 1 are instructed to order 
blood tests immediately at the first consultation. Those in 
group 2 are instructed to restrict blood test ordering to 
patients with complaints persisting after four weeks. GPs 
in group 3 are also instructed to try and postpone test 
ordering, but they also participate in a quality improve­
ment strategy that supports them in postponing test 
ordering for patients with unexplained complaints. The 
study design includes two sub-studies. The first is a diag­
nostic study comparing patients from group 1 (immediate 
test ordering) with patients from groups 2 and 3 (4 weeks 
of watchful waiting). The second is a quality improvement 
study, comparing group 2 (instruction to postpone test 
ordering) with group 3 (instruction to postpone test 
ordering plus quality improvement strategy) in terms of 
the actual postponement of test ordering.
The reason why we decided to randomise general practices 
instead of patients or individual GPs is that we assumed 
there would be contamination, for three reasons. Firstly, it 
is not possible for GPs to selectively use the communica­
tion skills they have learnt during the quality improve­
ment strategy in one patient and fall back to their previous 
behaviour in the next patient. Secondly, in group prac­
tices, patients are sometimes seen by different colleagues 
at different appointments. If these GPs are in different 
intervention arms, this may bias the results. Thirdly, 
patients of different GPs within one practice may 
exchange experiences about the scientific research project 
they participate in. The randomisation procedure is car­
ried out separately for the two regions where the partici- 
patinjg university departments are located. To achieve 
allocation concealment, study groups are assigned to GPs 
by a random number seed computer program that ran­
domises in blocks and is operated by an experienced 
research assistant.
Procedure
If, after history taking and physical examination, a patient 
is considered to have unexplained complaints and gives 
informed consent, the GP enrols the patient in the study.
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Fig u re !
Randomisation scheme.
Depending on the GP's study arm, blood test ordering or 
a 4-week watchfUl waiting policy is suggested to the 
patient. All patients are asked to return to the GP if com­
plaints do not disappear within 4 weeks. If patients return, 
blood tests are ordered for every patient, irrespective of 
GPs' study arm. This means that patients in group 1 are 
then tested for the second time and patients in groups 2 
and 3 for the first time.
All tests are performed at the regional laboratory, accord­
ing to local standard operating procedures and using the 
local reference values.
Patient follow-up ends at 12 months after the initial con­
sultation.
Power calculation
Based on previous research, we estimated that approxi­
mately 2 percent of patients will eventually be diagnosed 
with serious pathology.[16] We estimated that 100 
patients with pathology will be needed to allow valid con­
clusions, which means that 5000 patients should be 
included in the study. Dutch GPs see approximately 500 
patients a month, of whom 1-5% are estimated to have 
unexplained complaints. This means that each GP could 
on average include 180 patients in one year. These figures 
mean that we need 27 GPs to participate. Assuming a 
patient refusal rate of approximately 50 percent, 54 GPs 
need to be recruited. A total of 5000 patients (approxi­
mately 1700 in each study group) would also be sufficient 
to determine the costs and effects of the quality improve­
ment strategy with enough precision.
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Participants
The project is being carried out in a two regions in the 
Netherlands, one in the south and one in the west.
GPs
For logistic reasons, only GPs associated with certain lab­
oratories for the handling of their test requests can partic­
ipate in the trial. These laboratories are situated in the 
western (Haarlem, Almere) and southern (Sittard, Weert, 
Geldrop, Eindhoven, Helmond, Veldhoven, 's Hertogen­
bosch) regions. No further GP participation criteria were 
formulated.
Patients
Patients aged 18 years and older, presenting with one of 
the unexplained complaints mentioned above, who have 
not consulted their GPs for this complaint in the previous
6 months and who are able to speak, read and write Dutch 
are eligible to be included in the study. GPs decide to ask 
patients to participate in the study after history taking and 
physical examination, so the decision to label the com­
plaints of a patient as unexplained is made entirely by the 
GPs. Excluded are patients with unexplained complaints 
for whom the GPs feel that watchful waiting would be 
unacceptable to them. Patients are asked to participate by 
their GPs. The GPs are asked to enrol each consecutive eli­
gible patient.
Blinding
Researchers
The researchers are not blinded for the trial group alloca­
tion of the participating GPs. They are not involved in the 
GPs' decision to label patients as having unexplained 
complaints, nor in the test ordering procedure or the 
reporting of the results of the laboratory tests.
GPs
The GPs are not blinded for the trial group they are ran­
domised to, but they are for the content and format of the 
quality improvement strategy that aims to support GPs in 
postponing test ordering. In addition, only those test 
results from the set of tests we decided to include in the 
study (see the section entitled 'Diagnostic intervention at 
patient level' below) they ordered themselves are fed back 
to them, so they are partially blinded to the test results. 
Since the effects of test results on the treatment given to 
patients and on their clinical course are outcome meas­
ures of our study, we do not aim at complete blinding to 
the test results.
Patients
Patients in group 1 are fully informed about the blood 
testing options, whereas patients from groups 2 and 3 are 
kept naive about the possibility of getting blood tests 
ordered. All patients are blinded for the possibility that
their GP is participating in a quality improvement strat­
egy. In our opinion, full blinding is not possible because 
there is no placebo for blood testing that is feasible and 
ethically acceptable.
Laboratories
Laboratories are blinded for all patient characteristics 
except sex and age.
Diagnostic intervention at patient level 
Selection o f  blood tests
Members of an expert panel including GPs and hospital 
specialists (n = 20) have been individually asked to pro­
pose tests which they regarded as useful diagnostic tools 
in general practice for each of the 5 complaints. All tests 
mentioned at least twice were included in a complaint- 
specific set of tests (table 1). If not already included in the 
set, the four tests recommended in the NHG guideline 
(glucose, ESR, TSH and Hb) were added. In addition, iron 
parameters (transferrin saturation (TS) and ferritin), anti- 
endomysium and carbohydrate deficient transferrin 
(CDT) were added as indicators of haemochromatosis, 
celiac disease and alcohol abuse respectively. These three 
diseases can lead to unexplained complaints, are fre­
quently missed by GPs according to the literature and 
should be demonstrable with the above blood tests. The 
diagnostic accuracy of these tests in patients presenting 
with unexplained complaints in general practice has, 
however, not yet been established. [12,17-20]
Im m ediate blood test ordering
GPs from group 1 are instructed to order blood tests 
immediately when including a patient in the study. The 
GPs are free to decide on the number and type of blood 
tests. The patient takes the blood test ordering form to the 
regional laboratory participating in the study. At the labo­
ratory, the tests ordered by the GP are supplemented by 
the complaint-specific tests from the sets described in 
table 1. Only results of tests ordered by the GPs them­
selves are fed back. If a GP does not intend to order any 
tests (but is obliged to do so by the study protocol), the 
results of the four tests recommended by the NHG guide­
line are fed back, because patients expect results after a 
blood sample has been taken.
W atchfu l waiting for 4 weeks
GPs from groups 2 and 3 propose to the patients they 
include to observe a 4-week watchful waiting policy. 
When watchful waiting is not considered feasible by the 
GP, e.g. because a patient insists on being tested, test 
ordering is allowed. In that case, the GPs are asked to state 
the reasons for not postponing test ordering on a special 
form.
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T ab le  1: S ets o f laboratory tests p er com plain t
Fatig ue A b d o m in a l
co m p lain ts
M usculo- skeleta l 
co m p lain ts
W e ig h t
changes
Itch
Alkaline Phosphatase (AF)
Alanine aminotransferase (A LA T) 
Amylase
Anti-endomysium
Aspartate aminotransferase (ASAT) 
Bilirubin
Erythrocyte sedimentation rate (ESR) 
Carbohydrate-deficient transferrin 
(C D T)
Creatinin kinase (C K )
Creatinin
C-reactive protein (CRP) 
Differentiated leukocyte count 
Eosinophils 
Ferritin
Gamma glutamyl transferase (G G T) 
Glucose
Haemoglobin (Hb)
Potassium (K)
Latex fixation test
Lactate dehydrogenase (LDH)
Leukocyte count
Monosticon
Total IgE
Thyroid stimulating hormone (TSH) 
Transferrin saturation (TS)
Urea 
Uric acid
T o ta l n u m b e r of tests 17 18
x
x
x  
11 17 14
x
x
x
x x
x
x x
x
Reference standard
The nature of unexplained complaints implies that no 
proper gold standard exists. Hence, we opted for a delayed 
type cross-sectional study design.[21,22] In this type of 
design, the diagnosis after the 12-month follow-up period 
is used as a reference standard. This diagnosis is estab­
lished separately by two researchers, making use of infor­
mation from the GPs' patient records. Differences are 
discussed and consensus is sought. If consensus cannot be 
reached, the case is presented to an expert panel that takes 
the final decision. No restrictions are imposed on GPs as 
to patient management during follow-up.
Quality improvement strategy
Developm ent o f  the strategy
Determinants of blood test ordering for unexplained com­
plaints -  both those relating to the GPs and those relating 
to the patients -  have been identified previously.[11,23] 
Based on these determinants, a quality improvement 
strategy has been developed using a systematic procedure 
based on intervention mapping techniques.[15] The strat­
egy has been pilot-tested, after which slight adjustments 
were made based on the pilot results.
Content o f  quality im provem ent strategy
For each GP in group 3, the strategy consists of two small- 
group meetings and one outreach visit by the researchers 
to their practice. Table 2 provides more details on the con­
tent of the strategy. The first group meeting is led by a GP 
experienced in medical diagnostic decision-making and a 
behavioural scientist experienced in teaching communica­
tion skills, while the second meeting is tutored only by the 
behavioural scientist. The outreach practice visit is made 
by one of the researchers. We have also developed patient 
education leaflets and diaries, to be handed out by the 
GPs, and a video message about watchful waiting, to be 
shown in the waiting room. All materials have been devel­
oped by the research team.
Procedure
At the beginning of the trial, all GPs in group 3 are invited 
to the small group meetings, which are organised region­
ally, usually at the regional hospital. These meetings are 
held with an interval of approximately four weeks. After 
these meetings, an appointment is made for the practice 
visit, which takes place at least 3 months after the second
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T ab le  2: E lem en ts o f the quality im p ro vem en t strateg y
E le m e n ts  of strateg y
Contents of programme Small group meeting 1
Part 1: Interactive explanation of diagnostic value of diagnostic testing for unexplained complaints and 
effect of watchful waiting policy on diagnostic value.
Part 2: Discussion of difficulties experienced in practice when dealing with patients presenting with 
unexplained complaints. Goal setting to change behaviour in GPs' own practice.
Small group meeting 2
Part 1: Discussion about experiences with behaviour change. Searching for solutions to barriers that 
have arisen.
Part 2: Practicing difficult situations by means of video vignettes. Setting new goals to change own 
behaviour.
Practice visit
Discussing individuals' barriers to change and providing suggestions to overcome these, based on stage 
of change.
In between meetings, GPs get the opportunity to w ork on their goals to change their behaviour.
Materials -  Course book.
-  Leaflets for patients with information about unexplained complaints.
-  Diaries about complaints and food intake to hand out to patients to fill in and later discuss together.
-  Video message for the waiting room, explaining the use of watchful waiting.
group meeting. GPs are encouraged to prepare for the 
meetings by doing homework assignments.
Control group
GPs in group 2 are the control group for GPs in group 3. 
In order to ensure a maximum contrast, no strategy is 
offered to group 2.
Measurements
All measurement instruments, measurement times and 
variables are summarised in table 3.
Most questions in the questionnaires have been formu­
lated by the research team, based on topics found in the 
literature. Quality of life is measured by the RAND SF36, 
together with the thermometer of the Euroqol question­
naire. Both are widely used and have been validated exten- 
sively.[24-26]
Patients
Findings of history taking and physical examination are 
recorded on a prestructured complaint registration form 
by the GP after the consultation(s).
All patients are given the first questionnaire at the first 
consultation and a second questionnaire at the second 
consultation after 4 weeks. Patients who do not return to 
their GP after 4 weeks are sent a questionnaire by mail. 
Patients from all groups receive follow-up questionnaires 
by mail at 6 and 12 months after the initial consultation.
After 12 months, i.e. at the end of the follow-up period, 
data on the final diagnosis and health care consumption
are collected from the patients' records by the researchers 
(MB and HK).
Copies of test ordering and result forms are collected by 
the researchers (MB and HK) from the regional laborato­
ries.
GPs
Background data of all participating GPs are collected 
before the start of the patient inclusion process. Data on 
whether the GPs are satisfied with the consultation, 
whether they suspect serious pathology and whether they 
are certain about the diagnosis are collected from the 
complaint registration form. The GPs' test ordering behav­
iour is derived from the test ordering forms and the 
patient records. GPs in group 3 are asked to complete eval­
uation forms on process items of the quality improve­
ment strategy. In addition, the determinants of their 
change processes they mentioned are audiotaped during 
the practice visit that is part of the quality improvement 
strategy.
Data analysis
Primary outcome m easures o f  the diagnostic intervention 
The first primary outcome is the accuracy and added value 
of blood tests in detecting serious pathology (per test and 
in combinations relevant to general practice), related to 
and in addition to signs and symptoms. Serious pathol­
ogy is defined as pathology requiring treatment. The sec­
ond primary outcome is the effect of a 4-week 
postponement of test ordering on the blood test character­
istics.
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In stru m en t V a ria b les T im e  points P opulation M ethod
T 0 T l# T l .5 #  T 6 T I 2 - Provision
- P erso n  w ho  co m p lete s
qu estio n n a ire
(- C o m m e n ts )
GPs' background data Personal data x All GPs - By mail
Practice x - GP
characteristics
CME x
Laboratory facilities x
available in practice
Complaint Symptoms x x All patients - Present in practice
registration form (for
each individual type of
complaint)
Signs x x - GP
Working hypothesis x x
Degree of x x
unexplainedness
Degree of suspicion x x
of serious pathology
Degree of insecurity x x
of GP
Satisfaction of GP x x
Patients' background Date of birth x x x x x  All patients - Handed out by GP (T0, T l )
data (included in
patient questionnaire)
Country of birth x x x x x - By mail (T I.5 -T I2 )
Sex x x x x x - Patient
Marital status x x x x x
Type of health x x x x x
insurance
Level of education x x x x x
Patient questionnaire Intensity of x x x x x  All patients - Handed out by GP (T0, T l )
complaints
Course of complaints x x x x x - By mail (T I.5 -T I2 )
Satisfaction with care x x - Patient
Anxiety x x
Quality of life x x x x x
- RAND 36
- Euroqol
thermometer
Utilisation of health x x x x x
care
Test ordering form Quality of test x* x* All patients - Present in practice
ordering
Quantity of test x x - GP
ordering
Test result form Test results x * x* All patients - Laboratory
- Laboratory staff
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Record examination Final diagnosis x  All patients - Practice/university
form
Utilisation of health x - Researcher
care
Use of watchful x
waiting strategy
M eeting 1 M eeting 2 P ra ct ice
v is it
Reports of small Participation x x All GPs in - Meeting room
group meetings intervention group
Learning effects x x - Researcher
Evaluation forms of Valuation of
x x
All GPs in - Meeting room
small group meetings programme x x intervention group
Learning effects - Researcher
Suggestion for x x
improvement
GP interview in Barriers and x All GPs in - Practice
practice facilitators during x intervention group
change
Stages of change x x - GP
Cost registration Costs of development x - University
and organising of
strategy
- Researcher
* TO for patients randomised to group I, T l  for all patients but only if they revisit their GP
# T I is the time point to measure a follow-up visit by the patient 4 weeks after inclusion. If a patient does not return to the GP, a questionnaire is 
sent by mail after 6 weeks. This time point is indicated as T I .5 .
Primary outcome m easures o f  the quality im provem ent strategy 
The primary outcome of the quality improvement strategy 
is the quantity of tests ordered in relation to the instruc­
tion to either order blood tests immediately or to suggest 
a 4-week watchful waiting policy.
Secondary outcome m easures
The secondary outcome measures are summarised in table
4.
Types o f  analysis
An intention-to-postpone analysis will be performed. 
Longitudinal comparisons will be made using repeated 
measurements techniques and multilevel analysis to cor­
rect for potential clustering of outcomes in GPs and prac­
tices. Barriers to and facilitators of change are analysed 
qualitatively.
T ab le  4: S econ dary  ou tco m e m easures
Incidence of unexplained complaints in general practice
Predictive value of GPs' working hypothesis
Duration of unexplained complaints
Effect of unexplained complaints on patients' quality of life
Effect of immediate testing or watchful waiting on patients' satisfaction with care, anxiety, medical consumption and sick leave 
Effect of immediate testing or watchful waiting on GPs' satisfaction, anxiety and insecurity
Effect of quality improvement strategy on GPs' knowledge about the value of blood test ordering in unexplained complaints, communication skills 
and attitudes
Barriers to and facilitators of GPs proposing a watchful waiting strategy 
Costs of the quality improvement strategy
Page 9 of 11
(page number not for citation purposes)
BMC Family Practice 2006, 7:20 http://www.biomedcentral.eom/1471 -2296/7/20
Non-inclusion analysis
A non-inclusion analysis will be performed to check 
whether included patients are comparable to patients who 
are eligible but not included.
Discussion
Reasons for publishing this study design
This protocol describes an RCT which combines the gen­
eration of new clinical and epidemiological evidence to 
underpin guidelines on test ordering in unexplained com­
plaints with the implementation of these guidelines. To 
our knowledge, this is the first RCT to integrate questions 
on clinical epidemiology and quality of care. The first rea­
son for us to opt for this combination is that it meets sug­
gestions made in the literature to evaluate the value of 
diagnostic tests just as rigorously as is done with treat­
ments, namely by RCTs, and to pay attention to the imple­
mentation of evidence while generating it.[27] Secondly, 
both sub-studies require large numbers of participants 
with the same characteristics, and combining the two 
increases the efficient use of available resources. Apart 
from the advantages of the combination, however, we 
also need to mention one methodological disadvantage. 
Ideally, the evidence on which a quality improvement 
strategy is based should already be available at the start of 
development of the strategy, as it might influence its for­
mat. In the case of this study, evidence generation on one 
hand and the design and execution of the strategy on the 
other run in parallel. Evaluation at the end of the study 
should clarify whether the new evidence will necessitate 
alterations in either the diagnostic guidelines or the qual­
ity improvement strategy.
General reasons to publish the design of a study before the 
analyses have begun have been discussed by Godlee and 
De Bruijn et al.[28,29] In the case of the present study, 
there was an additional reason to do so. The design of the 
study presented here is rather complicated because, due to 
the nature of unexplained complaints, we had to seek 
methodological solutions that were not always straight- 
forward.[22] By presenting the decisions made in design­
ing this study, we are hoping to start a debate on proper 
methodology for research into unexplained complaints.
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